Goldenwell Biotech (GWLL) EBIAT (2019 - 2025)
Goldenwell Biotech filings provide 7 years of EBIAT readings, the most recent being -$7985.0 for Q3 2025.
- On a quarterly basis, EBIAT rose 65.38% to -$7985.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$75118.0, a 39.83% increase, with the full-year FY2024 number at -$131498.0, down 12.05% from a year prior.
- EBIAT hit -$7985.0 in Q3 2025 for Goldenwell Biotech, down from -$5220.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$4584.0 in Q3 2022 to a low of -$920332.0 in Q4 2022.
- Median EBIAT over the past 5 years was -$27536.0 (2024), compared with a mean of -$73585.9.
- Biggest five-year swings in EBIAT: tumbled 16053.42% in 2021 and later skyrocketed 97.74% in 2023.
- Goldenwell Biotech's EBIAT stood at -$29541.0 in 2021, then tumbled by 3015.44% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then crashed by 32.39% to -$27536.0 in 2024, then skyrocketed by 71.0% to -$7985.0 in 2025.
- The last three reported values for EBIAT were -$7985.0 (Q3 2025), -$5220.0 (Q2 2025), and -$34377.0 (Q1 2025) per Business Quant data.